Cardiovascular effects of melatonin receptor agonists.

摘要: Introduction: Melatonin synchronizes circadian rhythms with light/dark period and it was demonstrated to correct chronodisruption. Several melatonin receptor agonists improved pharmacokinetics or increased affinity are being developed, three of them already in clinical use. However, the actions extend beyond chronobiology cardiovascular metabolic systems as well. Given high prevalence disease their common occurrence chronodisruption, is utmost importance classify cardiometabolic effects newly approved putative melatoninergic drugs. Areas covered: In present review, available (although very sparse) data on such effects, particular by (circadin, ramelteon, agomelatine) clinically advanced (tasimelteon, piromelatine = Neu-P11, TIK-301) compounds summarized. The authors have searched for an association blood pressure, vascular reactivity, ischemia, myocardial remodeling...